| Similar Articles |
|---|
 |
Chemistry World
January 15, 2008
Hepeng Jia |
Huge Project to Boost Chinese Drug Development The Chinese government has agreed a multi-billion drug development funding program to boost innovation in its generics-dominated pharmaceutical sector.   |
Bio-IT World
Dec 2005/Jan 2006
Salvatore Salamone |
Gates, Clinton Address Global Health Summit The conference brought together leaders in business, government, medicine, public philanthropic groups, and the arts to address and develop solutions to the world's heath crises. |
Nurse Practitioner
December 2009
Gujral & Collantes |
Understanding Viral Hepatitis: A guide for primary care Recent advancements in the field of genomics and proteomics technology have given researchers and clinicians more insight on disease pathogenesis and helped create more tailored approaches to the treatment of these conditions. |
American Family Physician
January 1, 2004 |
Hepatitis B Infection What is hepatitis B virus?... How can I tell if I have HBV infection?... What happens after HBV infection?... What health problems can chronic HBV infection cause?... How can I protect my liver if I have chronic HBV infection?... How can HBV infection be prevented?... etc. |
Chemistry World
May 31, 2013
Phillip Broadwith |
Japanese pharma opens compound vaults Japanese pharmaceutical companies are opening up their libraries of experimental compound as part of a new partnership program. The initiative aims to find new drugs for malaria, tuberculosis and neglected tropical diseases. |
Chemistry World
August 15, 2012 |
The latent threat of tuberculosis Although TB was close to being eradicated in the developed world, it is a major problem in developing countries. With drug-resistant strains on the increase, Clare Sansom outlines the latest in the fight against this killer disease |
Pharmaceutical Executive
September 1, 2011 |
Filling Front and Center in the Fight against TB Dr. Mel Spigelman, President and CEO of the TB Alliance, discusses the organization's priorities in developing treatments for tuberculosis. |
The Motley Fool
March 27, 2007 |
Fast Pitch: Vertex Pharmaceuticals 2007 is expected to be a very eventful year for the pharmaceutical, as it will furnish some important clinical trial results for its investigational drugs. Investors, take note. |
Pharmaceutical Executive
November 1, 2014
Casey McDonald |
Advocacy Beat: Progress in Global Access to TB Drugs Treatment Action Group reaches a milestone in improving access to much-needed treatments for tuberculosis. |
Chemistry World
October 31, 2008
Matt Wilkinson |
GSK Snaps up Hepatitis Drug Developer In a bid to strengthen its efforts to develop new hepatitis therapies, GSK has agreed to buy Genelabs Technologies in a deal worth $57 million. |
Pharmaceutical Executive
June 1, 2014
Jill Wechsler |
What Price Innovation? Payers, drug plans seek clear assessment of drug value to rationalize high drug prices. |
Pharmaceutical Executive
February 1, 2006
Joanna Breitstein |
Breath of Hope: TB in Africa For the first time in decades, the pharmaceutical industry has tuberculosis drugs in the pipeline. But it will take more than new pills to solve the problem. |
Chemistry World
February 14, 2011
Catherine Bacon |
New hepatitis C drug Scientists in the UK have developed a compound to combat the hepatitis C virus that could be taken as a pill. |
The Motley Fool
March 20, 2008
Brian Lawler |
Gilead Not Slowing Gilead Sciences gets a new approval for a drug. |
American Family Physician
January 1, 2004
Lin & Kirchner |
Hepatitis B Hepatitis B causes significant morbidity and mortality worldwide. Effective vaccines for hepatitis B virus have been available since 1982; infant and childhood vaccination programs introduced in the 1990s have resulted in a marked decrease in new infections. |
The Motley Fool
December 5, 2011
Alexander Crawford |
Ending HIV/AIDS: Hedge Funds Believe in These 5 Companies Do you think these companies will contribute to a cure? |
Pharmaceutical Executive
September 1, 2011 |
The Power of PDP Can cooperative ties between Big Pharma, NGOs, government, and international organizations pay the freight in making the fight against neglected diseases a permanent fix in global health? |
The Motley Fool
October 31, 2011
Brian Orelli |
Gunning for the Leaders Hepatitis C drugs take center stage. |
Chemistry World
December 9, 2009
Sarah Houlton |
New hep C breakthrough A drug being developed by Denmark's Santaris Pharma could provide a breakthrough in the treatment of hepatitis C, and positive results in a study on chimpanzees point to its potential to avoid drug resistance. |
The Motley Fool
August 10, 2010
Ryan McBride |
Vertex's Telaprevir Clears Hurdle, Could Halve Treatment Times for Hepatitis C Study results are positive. |
Chemistry World
October 2010
Bibiana Campos Seijo |
Editorial: Healing the world Although the role of science has not been strongly emphasised in discourse surrounding the Millennium Development Goals, the work of scientists contributes towards making the world a better place. |
IDB America
September 2001
Charo Quesada |
Against the odds Brazil emerges as a role model in the fight against AIDS... |
Smithsonian
November 2005 |
35 Who Made a Difference: Bill Gates The king of software takes on his biggest challenge yet: his foundation is reshaping the landscape of deadly and debilitating diseases in the developing world. |
The Motley Fool
July 27, 2011
Brian Orelli |
Good Combo; Too Bad There's Competition Vertex's VX-222 helps standard of care but still requires an injected medication. |
American Family Physician
November 1, 2001
Thomas R. Riley |
Preventive Strategies in Chronic Liver Disease Chronic liver disease is the 10th leading cause of death in the United States. Preventive care can significantly reduce the progression of liver disease. Part I: Alcohol, Vaccines, Toxic Medications and Supplements, Diet and Exercise... |
Scientific American
February 2009
John Rennie |
Tuberculosis, The Unromantic Killer Tuberculosis has never stopped being one of the world's most lethal infections |
The Motley Fool
March 31, 2011
Brian Orelli |
Hepatitis C Drugs Heat Up The current hepatitis C drugs stink. Who's ahead in the race to find new ones? |
Chemistry World
January 3, 2013
Andrew Turley |
TB drug milestone for bedaquiline Bedaquiline (sirturo) has become the first drug to be approved in the US for the treatment of multi-drug resistant tuberculosis |
The Motley Fool
January 9, 2012
Travis Hoium |
Idenix Pharmaceuticals Shares Jumped: What You Need to Know Shares of Idenix Pharmaceuticals got a positive diagnosis today and climbed 43% after the company released positive data for its hepatitis C drug. |
Finance & Development
December 1, 2007 |
Is the Global Health System Broken Three points of view on how the global health system can be improved: Making Markets Work by Joe Cerrell... Finding a Unified Vision by Helen Gayle and J. Stephen Morrison... Targeting the Health MDGs by Tore Godal... |
American Family Physician
June 15, 2006
Brundage & Fitzpatrick |
Hepatitis A The introduction of hepatitis A vaccines in 1995 led to a drop in the number of reported cases of hepatitis A and a shift to a higher percentage of cases occurring in older age groups. The hepatitis A virus survives for extended periods in the environment. |
AskMen.com
Dustin Driver |
Most Contagious Diseases Super-contagious diseases spread like wildfire. The best way to battle any of these nasty bugs is to avoid them altogether. Keep your eyes open for these most-unwanted diseases, and stay healthy. |
Wired
July 24, 2007
Thomas Goetz |
The Ultimate Diagnostic Device (By the Way, You've Got Drug-Resistant TB!) The CDC's goal of a tuberculosis-free society grew short due to the development of drug-resistant strains. But new standards for detection are in the works. |
HHMI Bulletin
Feb 2012
Nancy Ross-Flanigan |
A Safer Shot at TB While trying to understand tuberculosis bacteria genes, researchers discovered a safe way to shut down the bacteria. |
The Motley Fool
June 27, 2008
Brian Lawler |
Difficult Obstacles for SciClone With all the new technologies and discoveries, some drugmakers are undoubtedly going to be left in the dust. SciClone Pharmaceuticals, with its lead drug Zadaxin, might be one such drugmaker. |
Chemistry World
March 25, 2009
Hayley Birch |
TB's defence mechanism revealed The research could eventually lead to new drugs for TB, which remains one of the biggest killers among infectious diseases worldwide. |
CRM
August 2, 2004 |
The Pulse: Is your CRM initiative designed to... What's your CRM initiative designed to do, meet customer needs or internal needs? Results of a reader poll. |
